The Leeds Teaching Hospitals NHS Trust


Research

REMAP-CAP


Summary

This is an international randomised controlled trial, looking at the effect of a number of different drugs has on those with significant community-acquired pneumonia.   It is targeted towards those who are in ICU.  Those who are on a Covid-19 ward should be directed towards the Recovery Trial.

Priority

This is a study which is considered a national priority.

Treatment

Participants will be randomised into one of a number of treatment arms, depending on local drug availability, including

  • steroids,
  • macrolides,
  • antivirals and
  • immunomodulators 

Who can participate?

Patients will be eligible if they are

  1. Adults admitted to ICU
  2. Symptoms
  3. Confirmation of SARS-CoV-2 infection by PCR
  4. No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial. The R&I Team have expertise to be able to guide on this.

External Trial Website

https://www.remapcap.org/protocol-documents